iiCON launches new platform for long-acting medicines  

The Infection Innovation Consortium: iiCON has launched a new agreement with the Centre of Excellence for Long-Acting Therapeutics (CELT) at the University of Liverpool that will enable iiCON partners and collaborators to access the expertise and capability at CELT. 

CELT is a research centre focused on the development and understanding of long-acting medicines. One of the organisation’s major ambitions is the equitable availability of long-acting treatments in low- and middle-income countries.  

The agreement will see CELT launch and operate a platform within iiCON, giving partners and collaborators of iiCON’s access to expertise and facilities in long-acting therapeutics.  

Long-acting therapeutics can have a huge impact for treatment and prevention of chronic diseases and other applications for acute diseases where multiple pharmaceutical doses are required for successful therapy. 

Professor Janet Hemingway, iiCON director, said: “We are delighted to be formally welcoming the Centre for Long-Acting Therapeutics to iiCON as a key platform within the consortium. Long-Acting Therapeutics is an incredibly exciting area with huge potential to transform the treatment of a number of diseases, such as TB or malaria prophylaxis. The centre has world-leading expertise and facilities that companies of all sizes will be able to access through iiCON and we look forward to seeing the innovation this collaboration will support.” 

Professor Andrew Owen, co-Director of CELT, said: “We very much look forward to working closely together with our colleagues within iiCON as we strive to expand understanding of long-acting drug delivery and apply technologies and know-how to catalyse medicine development for treatment and prevention of infectious diseases. We are proud to bring our expertise into the consortium which we hope will help support innovation in global health.” 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free